Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Jan;12(1):119-23.
doi: 10.2450/2014.0160-13. Epub 2013 Jan 2.

Plasma exchange and immunosuppressive therapy in a case of mild haemophilia A with inhibitors and a life-threatening lower limb haemorrhage

Chiara Ambaglio  1 , Fabio Lodo  1 , Alice Trinchero  1 , Nicola Ghidelli  1 , Cesare Perotti  2 , Claudia Del Fante  2 , Gabriella Gamba  1
Affiliations
Case Reports

Plasma exchange and immunosuppressive therapy in a case of mild haemophilia A with inhibitors and a life-threatening lower limb haemorrhage

Chiara Ambaglio et al. Blood Transfus. 2014 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
aPTT, FVIII level, inhibitors titre during the acute phase of bleeding and treatment.
See this image and copyright information in PMC

References

    1. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992;339:594–8. - PubMed
    1. Sultan Y. Prevalence of inhibitors in a population of 3435 haemophilia patients in France. French Hemophilia Study Group. Thromb Haemost. 1992;67:600–2. - PubMed
    1. Hay CR, Ludlam CA, Colvin BT, et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost. 1998;79:762–6. - PubMed
    1. Sharathkumar A, Lillicrap D, Blanchette VS, et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild haemophilia A. J Thromb Haemost. 2003;1:1228–36. - PubMed
    1. Eckhardt CL, Menke LA, van Ommen CH, et al. Intensive peri-operative use of factor VIII and the Arg593->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost. 2009;7:930–7. - PubMed

Publication types

Substances